This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 May;7(5):245.

doi: 10.1038/nrneurol.2011.57.

Multiple sclerosis: Benefits of alemtuzumab in MS

PMID: 21555993
DOI: 10.1038/nrneurol.2011.57

Comment

Multiple sclerosis: Benefits of alemtuzumab in MS

Heather Wood. Nat Rev Neurol. 2011 May.

. 2011 May;7(5):245.

doi: 10.1038/nrneurol.2011.57.

Author

PMID: 21555993
DOI: 10.1038/nrneurol.2011.57

No abstract available

PubMed Disclaimer

Comment on

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass AD, Wynn DR, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA. Coles AJ, et al. Lancet Neurol. 2011 Apr;10(4):338-48. doi: 10.1016/S1474-4422(11)70020-5. Lancet Neurol. 2011. PMID: 21397567 Clinical Trial.

References

1. Lancet Neurol. 2011 Apr;10(4):338-48 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.